ArticleBMJ open respiratory research2023
Comorbidities and mortality among patients with chronic obstructive pulmonary disease.
Article in BMJ open respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- All-Cause and Cause-Specific Mortality in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- Article
- GOLD 2026 COPD ABE assessment tool to identify individuals at high risk in a UK multicentre COPD cohort (ERICA).BMJ open respiratory research · 2026Article
- Polypharmacy and Drug-Drug Interactions in Chronic Obstructive Pulmonary Disease: A Narrative Clinical Review.Pharmaceutics · 2026Review
- Determinants of All-Cause Mortality in Spirometry-Confirmed COPD in Primary Care: A Population-Based Multidimensional Cohort Study.Journal of clinical medicine · 2026Article
- Ultrasonographic diaphragmatic assessment as an emergency mortality predictor in acute exacerbation of COPD.International journal of emergency medicine · 2026Article
- Mitigating chronic respiratory disease through the lens of multimorbidity: the MARES mixed-methods study protocol.BMJ open · 2026Article
- Coronary heart disease and chronic obstructive pulmonary disease prevalence and temporal trends among United States adults: a national population-based study.Frontiers in epidemiology · 2026Article
- Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.Frontiers in pharmacology · 2026Article
- Development and Real-World Evaluation of an Interpretable Machine Learning Framework for Predicting COPD-Related Healthcare Costs.International journal of chronic obstructive pulmonary disease · 2026Article
- Association Between Cardiovascular Comorbidities and Clinical Outcomes in Patients Hospitalized for AECOPD.International journal of chronic obstructive pulmonary disease · 2026Article
- A Narrative Review of the Correlation Between Comorbidity and Acute Exacerbation of COPD Patients.International journal of chronic obstructive pulmonary disease · 2026Review
- Chronic Obstructive Pulmonary Disease in Never-Smokers-A Distinct Entity Within the COPD Spectrum.Life (Basel, Switzerland) · 2025Review
- Impact of Diabetes Mellitus on 30-Day Mortality and Ventilation Outcomes in Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD): A Retrospective Cohort Study.Life (Basel, Switzerland) · 2025Article
- Prognostic risk profiling in COPD using Global Initiative for Chronic Obstructive Lung Disease 2023 ABE and comorbidity assessment: evidence from a register-based COPD cohort.Journal of global health · 2025Article
- Increasing Quality and Quantity of Life in Individuals with Chronic Obstructive Pulmonary Disease: A Narrative Review with an Emphasis on Pulmonary Rehabilitation.Life (Basel, Switzerland) · 2025Review
- Adverse Outcomes Associated With Inhaled Corticosteroid Use in Individuals With Chronic Obstructive Pulmonary Disease.Annals of family medicine · 2025Article
- Comorbidities and Cause of Death in COPD Patients Compared to Non-COPD Controls: An 8-year Observational Retrospective Healthcare Claims Database Cohort Study.International journal of chronic obstructive pulmonary disease · 2025Observational
- Trends in initial pharmacological COPD treatment in primary care (2010-2021): a population-based study using the PHARMO Data Network.Respiratory research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionComorbidities are common in patients with chronic obstructive pulmonary disease (COPD). Estimates of prevalence, incidence and prognostic impact of comorbidities provide foundational knowledge of COPD epidemiology. We examined the prevalence, incidence and prognostic impact of 21 comorbidities among patients with COPD compared with the Danish general population.
methodsWe conducted a nationwide, population-based cohort study based on longitudinal Danish registry data, covering all Danish hospitals (2010-2021). The cohorts comprised 142 973 patients with a first-time hospital-based diagnosis of COPD and 428 917 age-matched and sex-matched comparators from the general population. During follow-up, we estimated the 5-year risk and risk difference, using competing risk methods when applicable.
resultsAt time of diagnosis, the comorbidities with the highest prevalence were mood, stress-related or anxiety disorders (25.2% for patients with COPD vs 13.1% for comparators), osteoporosis/hip fractures (17.4% vs 9.9%), diabetes (15.6% vs 10.5%), peripheral arterial disease (13.5% vs 4.9%) and heart failure (13.3% vs 4.0%). During follow-up, the risk of most incident comorbidities was markedly elevated among patients with COPD. The five comorbidities associated with the highest 5-year absolute risk difference with respect to the risk in the general population were mood, stress-related or anxiety disorders (5.7%), osteoporosis/hip fractures (5.6%), heart failure (4.2%), smoking-related cancers (2.8%) and peripheral arterial disease (2.7%). The 5-year mortality risk was 43% vs 17.7%. Among patients with COPD, the 5-year mortality risk markedly increased with the number of comorbidities present.
conclusionsOur population-based findings underscore the importance of considering comorbidities in the management of COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.